)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Vor Biopharma
Vor Biopharma (VOR) investor relations material
Vor Biopharma 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic transformation and vision
Pivoting to an autoimmune-focused company, leveraging telitacicept as a lead asset, with a shift completed by mid-2025.
Aims to transform treatment of B cell-driven autoimmune diseases with a selective BAFF/APRIL inhibitor, telitacicept.
Focus on global expansion, targeting large, underserved patient populations in myasthenia gravis and Sjögren's disease.
Company is well-capitalized with $450 million, supporting operations and milestones through mid-2028.
Assembled a leadership team with deep expertise in autoimmune disease, commercial strategy, and clinical development.
Clinical development and milestones
Global Phase 3 trial for myasthenia gravis underway, with topline data expected in 1H27.
Global Phase 3 trial for Sjögren's disease to initiate in 1H26.
Telitacicept has demonstrated efficacy and safety in eight autoimmune diseases, with commercial approvals in China for lupus, RA, and MG.
MG Phase 3 data from China show significant and durable symptom improvement, with nearly symptom remission at week 48.
Expansion opportunities identified in additional B cell-mediated autoimmune diseases.
Mechanism of action and clinical efficacy
Telitacicept is a TACI-Fc fusion protein that inhibits both BAFF and APRIL, targeting autoreactive B cells and plasma cells.
Demonstrates disease modification by reducing pathogenic B cells and autoantibody production.
Clinical trials show largest placebo-adjusted improvement in MG-ADL for myasthenia gravis and robust, durable ESSDAI reduction in Sjögren's disease.
Over 10,000 patients treated in China, with robust safety and efficacy data across multiple autoimmune indications.
Telitacicept positioned as best- and first-in-class BAFF/APRIL inhibitor with potential for broad commercial success.
Mitigate global variability in China data?
Key protocol changes for Sjögren's trial?
Prioritize future indication selection?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vor Biopharma earnings date
Q4 202520 Mar, 2026
Vor Biopharma
Next Vor Biopharma earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for blood cancers. The company's approach combines cell and genome engineering to create therapies that target and treat hematological malignancies. Vor's proprietary platform primarily involves engineering hematopoietic stem cells (HSCs) to enhance their compatibility with targeted therapies. The lead product candidate, an engineered HSC known as tremtelectogene empogeditemcel (trem-cel), is currently in clinical trials for the treatment of acute myeloid leukemia (AML). Vor is also working on additional therapies that involve chimeric antigen receptor T-cells (CAR-T) and antibody-drug conjugates to further expand its cancer treatment portfolio. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage